WeTrials
Recruiting

A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations

What is this study?

This study is testing an investigational cancer medicine called plixorafenib in patients whose tumors have a specific genetic change known as a BRAF alteration. Researchers want to see how safe this targeted therapy is and how well it works against different types of advanced solid tumors and brain tumors.

Who can participate?

You may be able to join if you are at least 8 years old, weigh over 55 pounds, and have a confirmed solid tumor or brain tumor with a proven BRAF gene change. However, you cannot join if you have previously been treated with certain similar cancer drugs like RAF or MEK inhibitors, or if you have a conflicting RAS gene mutation.

What will happen?

Participants in this trial will receive the investigational study drug, plixorafenib, which is designed to target specific cancer cell changes. Your health and your tumor's response to the treatment will be closely monitored by the study doctors throughout the process.

Where and when?

This study is currently recruiting participants at locations in California, including Beverly Hills, San Francisco, and Los Angeles. More sites may also be available.

Key Points
  • 1Testing an investigational targeted cancer therapy called plixorafenib
  • 2For patients aged 8 and older with specific BRAF gene changes in their tumors
  • 3Currently actively recruiting patients at multiple medical centers in California

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Cancer Harboring BRAF AlterationsHGGLGGSolid Tumors

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.